{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:56:56Z","timestamp":1794315416984,"version":"4.9.0"},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,2,15]]},"DOI":"10.2169\/internalmedicine.1969-23","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T22:12:55Z","timestamp":1687299175000},"page":"481-486","source":"Crossref","is-referenced-by-count":9,"title":["Effect of Infliximab on Chronic Progressive Neuro-Beh\u00e7et's Disease: Influence of the Timing of Introduction on the Patient Outcome"],"prefix":"10.2169","volume":"63","author":[{"given":"Shunsei","family":"Hirohata","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Nobuhara Hospital, Japan"},{"name":"Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Japan"},{"name":"Department of Internal Medicine, Teikyo University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Teikyo University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tokyo Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Kawachi","sequence":"additional","affiliation":[{"name":"Comprehensive Medical Education Center, Niigata University School of Medicine, Japan"},{"name":"Department of Neurology, Brain Research Institute, Niigata University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kirino","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Ishigatsubo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Takeno","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical University Musashi Kosugi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hisanaga K. Neuro-Beh\u00e7et's disease, neuro-Sweet disease, and spectrum disorsders. Intern Med 61: 447-450, 2022.","DOI":"10.2169\/internalmedicine.8227-21"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Al-Araji A, Kidd D. Neuro-Beh\u00e7et's disease: epidemiology, clinical characteristics, and management. Lancet Neurol 8: 192-204, 2009.","DOI":"10.1016\/S1474-4422(09)70015-8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hirohata S, Kikuchi H, Sawada T, et al. Clinical characteristics of neuro-Behcet's disease in Japan: a multicenter retrospective analysis. Mod Rheumatol 22: 405-413, 2012.","DOI":"10.3109\/s10165-011-0533-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Akman-Demir G, Serdaroglu P, Tas\u00e7i B. Clinical patterns of neurological involvement in Beh\u00e7et's disease: evaluation of 200 patients. Brain 122: 2171-2182, 1999.","DOI":"10.1093\/brain\/122.11.2171"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hirohata S, Isshi K, Oguchi H, et al. Cerebrospinal fluid interleukin-6 in progressive Neuro-Beh\u00e7et's syndrome. Clin Immunol Immunopathol 82: 12-17, 1997.","DOI":"10.1006\/clin.1996.4268"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hirohata S. Potential new therapeutic options for involvement of central nervous system in Beh\u00e7et's disease (Neuro-Beh\u00e7et's syndrome). Curr Rheumatol Rev 3: 297-303, 2007.","DOI":"10.2174\/157339707782408973"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hirohata S, Suda H, Hashimoto T. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Beh\u00e7et's disease. J Neurol Sci 159: 181-185, 1998.","DOI":"10.1016\/S0022-510X(98)00165-8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ishido M, Horita N, Takeuchi M, et al. Distinct clinical features between acute and chronic progressive parenchymal neuro-Beh\u00e7et disease: meta-analysis. Sci Rep 7: 10196, 2017.","DOI":"10.1038\/s41598-017-09938-z"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kikuchi H, Takayama M, Hirohata S. Quantitative analysis of brainstem atrophy on magnetic resonance imaging in chronic progressive neuro-Beh\u00e7et's disease. J Neurol Sci 337: 80-85, 2014.","DOI":"10.1016\/j.jns.2013.11.020"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kikuchi H, Aramaki K, Hirohata S. Low dose MTX for progressive neuro-Beh\u00e7et's disease. A follow-up study for 4 years. Adv Exp Med Biol 528: 575-578, 2003.","DOI":"10.1007\/0-306-48382-3_117"},{"key":"11","unstructured":"11. Sarwar H, McGrath H Jr, Espinoza LR. Successful treatment of long-standing neuro-Beh\u00e7et's disease with infliximab. J Rheumatol 32: 181-183, 2005."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Piptone N, Olivieri I, Padula A, et al. Infliximab for the treatment of neuro-Beh\u00e7et's disease: a case series and review of the literature. Arthritis Rheum 59: 285-290, 2008.","DOI":"10.1002\/art.23345"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive neuro-Beh\u00e7et's syndrome. J Neurol Sci 272: 99-105, 2008.","DOI":"10.1016\/j.jns.2008.05.002"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Beh\u00e7et disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 95: e3863, 2016.","DOI":"10.1097\/MD.0000000000003863"},{"key":"15","first-page":"1078","volume":"335","author":"International Study Group for Beh\u00e7et's Disease null","year":"1990","unstructured":"15. International Study Group for Beh\u00e7et's Disease. Criteria for diagnosis of Beh\u00e7et's disease. Lancet 335: 1078-1080, 1990.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 35: 498-502, 1992.","DOI":"10.1002\/art.1780350502"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hirohata S, Kikuchi H, Sawada T, et al. Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Beh\u00e7et's disease. J Neurol Sci 349: 143-148, 2015.","DOI":"10.1016\/j.jns.2015.01.005"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Hamada K, Takei R, Sakiyama Y, et al. A case of chronic progressive neuro-Beh\u00e7et disease with extensive cerebral atrophy and elevated CSF IL-6 activity treated with infliximab. Rinsho Shinkeigaku 58: 30-34, 2018 (in Japanese, Abstract in English).","DOI":"10.5692\/clinicalneurol.cn-001086"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Hirohata S, Kikuchi H, Sawada T, et al. Recommendations for the management of neuro-Beh\u00e7et's disease by the Japanese National Research Committee for Beh\u00e7et's Disease. Intern Med 59: 2359-2367, 2020.","DOI":"10.2169\/internalmedicine.4705-20"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Takahashi S, Sanjo N, Miyamoto S, et al. Width of the third ventricle as a highly-sensitive biomarker in chronic progressive neuro-Behcet's disease. J Neurol Sci 421: 117284, 2021.","DOI":"10.1016\/j.jns.2020.117284"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/4\/63_1969-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:31:03Z","timestamp":1715574663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/4\/63_1969-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1969-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]},"article-number":"1969-23"}}